<SEC-DOCUMENT>0001193125-23-159993.txt : 20230605
<SEC-HEADER>0001193125-23-159993.hdr.sgml : 20230605
<ACCEPTANCE-DATETIME>20230602181958
ACCESSION NUMBER:		0001193125-23-159993
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230602
FILED AS OF DATE:		20230605
DATE AS OF CHANGE:		20230602

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		23990586

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d497070d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated June 02, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 33, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d497070dex991.htm">Immutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement Offer
</A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: June 02, 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d497070dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g497070image1.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2&nbsp;June 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Successfully
Completes Institutional Placement and Institutional Component of its Entitlement Offer </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep Limited, an Australian company (ASX: IMM) (Nasdaq:
IMMP) (<B>Immutep</B><B> </B>or the <B>Company</B>), is pleased to announce the successful completion of an institutional placement (<B>Placement</B>) and the institutional component (<B>Institutional Entitlement Offer</B>) of its 1 for 7.6 pro rata
accelerated <FONT STYLE="white-space:nowrap">non-renounceable</FONT> entitlement offer (<B>Entitlement Offer </B>and, together with the Placement, the<B> Offer</B>) of new fully paid ordinary shares in Immutep (<B>New</B><B> </B><B>Shares</B>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is conducting a fully underwritten Offer of approximately A$80&nbsp;million comprising the Placement and the Entitlement Offer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Placement and Institutional Entitlement Offer (together, the <B>Institutional</B><B> </B><B>Offer</B>) closed on Wednesday, 31&nbsp;May 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Institutional Offer raised gross proceeds of approximately A$67.9&nbsp;million at an offer price of A$0.26 per New Share, consisting of approximately
A$50&nbsp;million under the Placement and approximately A$17.9&nbsp;million under the Institutional Entitlement Offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following completion of the Offer
Immutep will be fully funded for its current and expanded clinical program through to Q1 2026 with a <FONT STYLE="white-space:nowrap">pro-forma</FONT> cash balance of A$135.2&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr Russell Howard, Chairman of Immutep, said:&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;This funding received from the Offer will support our new registrational Phase III <FONT STYLE="white-space:nowrap">TACTI-004</FONT> trial in 1st line <FONT
STYLE="white-space:nowrap">non-small</FONT> cell lung cancer to critical interim results<SUP STYLE="font-size:75%; vertical-align:top">1</SUP>, our ongoing Phase IIb <FONT STYLE="white-space:nowrap">TACTI-003</FONT> study in head and neck small cell
carcinoma to its final data read out and our Phase II / III <FONT STYLE="white-space:nowrap">AIPAC-003</FONT> trial in metastatic and triple negative breast cancer to its Phase II read-outs. It will also enable us to continue our expansion strategy
for efti with funding for additional efficacy signal studies in different settings, and to potentially conduct a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase I trial<SUP
STYLE="font-size:75%; vertical-align:top">2</SUP> for IMP761, the world&#146;s first and only <FONT STYLE="white-space:nowrap">LAG-3</FONT> agonist, for autoimmune disease.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Shares subscribed for under the Institutional Offer are expected to be settled on Wednesday, 7&nbsp;June 2023 in Australia and to be issued on Thursday,
8&nbsp;June 2023. New Shares issued under the Institutional Offer will rank equally with existing fully paid ordinary shares in Immutep as at their date of issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The retail component of the Entitlement Offer is expected to open on 6&nbsp;June 2023. Existing retail shareholders with registered addresses in Australia or
New Zealand may participate in that retail component of the Entitlement Offer on the same terms as the Institutional Entitlement Offer. Persons in the United States may not participate in the retail component of the Entitlement Offer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical stage biotechnology
company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT
STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio harnesses its unique ability to </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Critical <FONT STYLE="white-space:nowrap">TACTI-004</FONT> interim results will be used in futility analysis to
determine whether or not the trial is likely to meet its objective. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Depending on, among other things, outcome of toxicology studies and costings. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>,
Level 33, Australia Square, 264 George Street, Sydney NSW 2000, Australia<B> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B></B><U>www.immutep.com</U> ABN: 90 009 237 889<B>
</B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g497070image1.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to
maximise value for shareholders. For more information, please visit <U>www.immutep.com</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Not an
offer of securities in the United States </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in
the United States. The New Shares have not been, and will not be, registered under the US Securities Act of 1933 (the <B>US Securities </B><B>Act</B>) or the securities laws of any state or other jurisdiction of the United States, The New Shares may
not be offered or sold in the United States except in a transaction registered under the US Securities Act or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and applicable US
state securities laws. No person in the United States is not eligible to participate in the Retail Entitlement Offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement contains certain
&#147;forward-looking statements&#148; including but not limited to projections, that are based on management&#146;s beliefs, assumptions and expectations and on information currently available to management. Forward-looking statements can generally
be identified by the use of forward-looking words such as, &#147;expect&#148;, &#147;anticipate&#148;, &#147;likely&#148;, &#147;intend&#148;, &#147;should&#148;, &#147;could&#148;, &#147;may&#148;, &#147;predict&#148;, &#147;plan&#148;,
&#147;propose&#148;, &#147;will&#148;, &#147;believe&#148;, &#147;forecast&#148;, &#147;estimate&#148;, &#147;target&#148; &#147;outlook&#148;, &#147;guidance&#148; and other similar expressions within the meaning of securities laws of applicable
jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are strongly cautioned not to place undue reliance on forward-looking statements, particularly in light of the current economic
climate and the significant volatility, uncertainty and disruption to equity and capital markets. Any such statements, opinions and estimates in this announcement speak only as of the date hereof and are based on assumptions and contingencies
subject to change without notice, as are statements about market and industry trends, projections, guidance and estimates. Forward-looking statements are provided as a general guide only. The forward-looking statements contained in this announcement
are not indications, guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Immutep and its subsidiaries, and may involve significant elements
of subjective judgement and assumptions as to future events which may or may not be correct. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>,
Level 33, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><U></U></B><U>www.immutep.com<B></B></U><B> </B>ABN: 90 009 237
889<B> </B></P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g497070image1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g497070image1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1$$17AI9@  34T *@    @ ! $[  (
M   3   (2H=I  0    !   (7IR=  $    F   0UNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $QA:W-H86YI
M(%)U=V%N<'5R80    60 P "    %   $*R0!  "    %   $,"2D0 "
M S0T  "2D@ "     S0T  #J'  '   (#   "*      '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M4X#+SZ?4\U:H HZ=>OJ&^98S';CY%#C#%A][\ >/J#7D?C+_ )*?+_UW@_\
M04KV:"!+>+RXAA=S-C.>223^I-8U]X,T34=5.I7=JSW3,K%Q*PY7&. <=A0!
MNT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
:1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
